Recent Advances in the Treatment of Lymphoma

Slides:

Advertisements

Similar presentations

Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, :00 PM.

Advertisements

Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.

Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496) Subset: 237 FL pts CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone)

Follicular & Aggressive B-Cell Lymphomas. Five-year TTF and Response Duration (RD) According to FLIPI Risk Group R-CHOPCHOPP value TTF Low-risk

MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.

Background Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. It’s account for about one-third of all.

Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.

NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.

Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.

Ruan J et al. Proc ASH 2013;Abstract 247.

Rituximab Maintenance versus Wait and Watch After Four Courses of R-DHAP Followed by Autologous Stem Cell Transplantation in Previously Untreated Young.

ASH 2009: Community Perspectives on Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Moderator John Leonard, MD Professor of Medicine Weill Cornell.

Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.

Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled.

Chen R et al. Proc ASH 2015;Abstract 518.

Lymphoma NICE guidelines July 2016

Fujiwara H et al. Proc ASH 2015;Abstract 181.

Mantle Cell Lymphoma: Approach to Induction Therapy

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Improving Survival in Glioblastoma Multiforme

Innovations and Issues in Mantle Cell Lymphoma

Relapsed/Refractory Follicular Lymphoma Conundrums

Updates in Hodgkin Lymphoma

Hot Topics in Lymphoma Supportive Care

The ABCs of AF.

Peripheral T-Cell Lymphoma in 2013

Prolonging Progression-Free Survival in Follicular Lymphoma

Activity Goals. Activity Goals Discussion Topics.

Treating Transplant-Ineligible Patients With Multiple Myeloma

Goals of Therapy in Relapsed CLL

Advances in Lymphoma.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Updates in Follicular Lymphoma

Activity Goals. Activity Goals Case Presentation.

Expert Perspectives on HSCT: Planning for Success

Jonathan W. Friedberg M.D., M.M.Sc.

Treatment Decisions in Chemorefractory Follicular Lymphoma

Updates in Lymphoma From Recent Congresses

Jonathan W. Friedberg M.D., M.M.Sc.

CD30 and Lymphoma: Pathology in Practice

Advances in Multiple Myeloma

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Evaluating Next-Generation BTK Inhibitors

Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma,

Navigating New Oral Treatment Algorithms in CLL

Targeting BTK Signaling in B-Cell Malignancies

Risk Stratification in CAD and PAD

Stephen Ansell, MD, PhD Mayo Clinic

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Updates in the Management of Acute Promyelocytic Leukemia

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.

Practical Guidance on the Management of Pan-Negative NSCLC

Zaja F et al. Proc ASH 2010;Abstract 966.

Proteasome Inhibitors and Patients

Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Ahmadi T et al. Proc ASH 2011;Abstract 266.

The ABCs of AF.

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma Stephen.

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.

Changing Paradigms in Relapsed/Refractory Indolent NHL

Risk Stratification in MDS

Rethinking Risk Stratification for Nonischemic HF:

Treatment Initiation and Selection in Newly Diagnosed CLL

Presentation transcript:

Recent Advances in the Treatment of Lymphoma

Program Topics

Mantle Cell Lymphoma

First-Line and Second-Line Therapy[a,b]

Risk Stratification

Induction: Lenalidomide Plus Rituximab

Induction: Addition of Cytarabine to Immunochemotherapy Pre-ASCT

5-Year TTF

Induction: 15-Year Follow-Up of Nordic MCL2

Relapse: Lenalidomide vs Investigator’s Choice

Relapse: Ibrutinib vs Temsirolimus

Relapse: Post-Ibrutinib Outcomes

Recent Advances in the Treatment of Lymphoma

DLBCL: Evaluation

Biomarker Frequency

Double Hit vs Double Protein (Expresser)

The Current Standard of Care

Strategies for Improving Outcomes for the Other 40%

EFS24

Examples of New Regimens

R(X) vs R-CHOP

R(X) vs R-CHOP (cont)

What Have We Learned?

Issues for Next Trials

Abbreviations

Abbreviations (cont)

Abbreviations (cont)